Protective effect of magnolol on oxaliplatin‐induced intestinal injury in mice

Abstract

Oxaliplatin (OXL) is the first line treatment therapy for gastrointestinal (GI) cancers and often combines with other chemotherapy. However, few reports have studied on its GI toxicity. Magnolol (MG), one of the mainly active constituents in Magnolia, has been reported to treat digestive diseases. Therefore, the purpose of this study is to evaluate the intestinal protective effect of MG in OXL treatment group. OXL administration mice showed body weight loss, diarrhea, and intestinal damage characterized by the shortening of villi and destruction of intestinal crypts, as well as the colon length change. MG significantly reduced body weight loss, alleviated diarrhea, reversed histopathological changes, and prevented colon length reduction. Oxidative stress and inflammation were activated after OXL, and these responses were repressed by MG through increasing the activities of superoxide dismutase, glutathione peroxidase, and glutathione, decreasing level of nuclear factor of kappa b and downregulating the following pro-inflammatory cytokines. Although the expression of tight junction protein occludin and numbers of proliferative crypt cells were reduced on ileum and colon after OXL, MG administration promoted these expressions. The fecal gut microbiota composition disturbed by OXL was significantly reversed by MG. Thus, MG could prevent the development and progression of mucositis induced by oxaliplatin through multipathway.

Magnolol additive improves growth performance of Linwu ducklings by modulating antioxidative status

“…Our data showed that magnolol decreased the levels of MDA, PC and 8-OHdG in serum or liver, which demonstrated that magnolol might modulate the antioxidant status of Linwu ducklings. Xia [50] found that magnolol suppressed oxidative stress in the small intestinal tissue of mice induced by oxaliplatin, which supported what was found in the present experiment. The mechanism of antioxidative effect with magnolol was uncertain.…”

Chemotherapy-Induced Intestinal Microbiota Dysbiosis Impairs Mucosal Homeostasis by Modulating Toll-like Receptor Signaling Pathways

“…(2) Increased abundance of Firmicutes and reduced abundance of Bacteroidetes [31,34,35], although conflicting results had also been reported [30,40,41]; (3) increased abundance of Gram-negative (G-) bacteria, including potential pathogenic microbes such as E. coli and Pseudomonas, and decreased abundance of Gram-positive (G+) bacteria, such as Bifidobacterium and Lactobacillus [7,27,28,[34][35][36][37]39,[41][42][43]. In addition, some intestinal bacteria were found translocated to mesenteric lymph nodes and spleen [38].…”

Effectiveness of Magnolol, a Lignan from Magnolia Bark, in Diabetes, Its Complications and Comorbidities—A Review

“…The changes caused by oxidative stress were inhibited; there was an increase in the activity of SOD, glutathione peroxidase (GPx) and the increase in the level of glutathione, as well as the decrease in the level of NF-κB and pro-inflammatory cytokines. Additionally, magnolol contributed to the restoration of the normal intestinal microflora, disturbed by the administration of oxaliplatin [ 136 ].…”